scholarly journals Characteristics, risk factors and case fatality rate of stroke in hospitalized patients in semi-urban South–South Nigeria

2013 ◽  
Vol 1 ◽  
pp. 205031211351611 ◽  
Author(s):  
Peter O Okokhere ◽  
Idowu A Bankole ◽  
Christian A Erohubie
Keyword(s):  
Risk Factors ◽  
Case Fatality Rate ◽  
Case Fatality ◽  
Hospitalized Patients ◽  
Fatality Rate ◽  
Urban South

scholarly journals Variations in case fatality and fatality risk factors of meningococcal disease in Western Norway, 1985–2002

2005 ◽  
Vol 134 (1) ◽  
pp. 103-110 ◽  
Author(s):  
I. SMITH ◽  
A. T. BJØRNEVIK ◽  
I. M. B. AUGLAND ◽  
A. BERSTAD ◽  
T. WENTZEL-LARSEN ◽  
...  
Keyword(s):  
Risk Factors ◽  
Skin Rash ◽  
Meningococcal Disease ◽  
Case Fatality Rate ◽  
Multivariate Analyses ◽  
Case Fatality ◽  
Fatality Rate ◽  
The Public ◽  
Admission Time ◽  
Meningococcal Septicaemia

SUMMARYIn a retrospective epidemiological study, 293 meningococcal disease patients hospitalized during 1985–2002, were examined for fatality and risk factors related to death. The overall case fatality rate (CFR) was 8·2%, but increased from 4% during 1985–1993 to 17% during 1994–2002. The latter 9-year period was characterized by more serogroup C infections and more patients with thrombocytopenia on admission to hospital. All patients categorized as meningitis on admission survived. Of the 24 patients who died, 21 had meningococcal skin rash on admission, 23 had an onset to admission time of ⩽24 h, and 16 had severe septicaemia with hypotension and/or ecchymoses without meningitis on admission. By multivariate analyses, a short onset to admission time, >50 petechiae, thrombocytopenia and severe septicaemia on admission were associated with fatality. More lives could be saved through earlier admission to hospital. This can be achieved through more information to the public about the early signs of meningococcal septicaemia, with the recommendation to look for skin rash in patients with acute fever during the first day and night.

scholarly journals Clinical Characteristics and Outcomes of COVID-19–Infected Cancer Patients: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Hua Zhang ◽  
Han Han ◽  
Tianhui He ◽  
Kristen E Labbe ◽  
Adrian V Hernandez ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Case Fatality Rate ◽  
Meta Analysis ◽  
Univariate Analysis ◽  
Case Fatality ◽  
The United States ◽  
Fatality Rate ◽  
Patients With Cancer ◽  
Increased Risk

Abstract Background Previous studies have indicated coronavirus disease 2019 (COVID-19) patients with cancer have a high fatality rate. Methods We conducted a systematic review of studies that reported fatalities in COVID-19 patients with cancer. A comprehensive meta-analysis that assessed the overall case fatality rate and associated risk factors was performed. Using individual patient data, univariate and multivariable logistic regression analyses were used to estimate odds ratios (OR) for each variable with outcomes. Results We included 15 studies with 3019 patients, of which 1628 were men; 41.0% were from the United Kingdom and Europe, followed by the United States and Canada (35.7%), and Asia (China, 23.3%). The overall case fatality rate of COVID-19 patients with cancer measured 22.4% (95% confidence interval [CI] = 17.3% to 28.0%). Univariate analysis revealed age (OR = 3.57, 95% CI = 1.80 to 7.06), male sex (OR = 2.10, 95% CI = 1.07 to 4.13), and comorbidity (OR = 2.00, 95% CI = 1.04 to 3.85) were associated with increased risk of severe events (defined as the individuals being admitted to the intensive care unit, or requiring invasive ventilation, or death). In multivariable analysis, only age greater than 65 years (OR = 3.16, 95% CI = 1.45 to 6.88) and being male (OR = 2.29, 95% CI = 1.07 to 4.87) were associated with increased risk of severe events. Conclusions Our analysis demonstrated that COVID-19 patients with cancer have a higher fatality rate compared with that of COVID-19 patients without cancer. Age and sex appear to be risk factors associated with a poorer prognosis.

scholarly journals Risk factors for incidence and case-fatality rates of healthcare-associated infections: a 20-year follow-up of a hospital-based cohort

2015 ◽  
Vol 144 (1) ◽  
pp. 198-206 ◽  
Author(s):  
R.-F. WANG ◽  
S.-H. SHEN ◽  
A. M.-F. YEN ◽  
T.-L. WANG ◽  
T.-N. JANG ◽  
...  
Keyword(s):  
Risk Factors ◽  
Mortality Rate ◽  
Incidence Rate ◽  
Case Fatality Rate ◽  
Tertiary Care ◽  
Case Fatality ◽  
Healthcare Associated Infections ◽  
Fatality Rate ◽  
Infection Site ◽  
Healthcare Associated

SUMMARYInformation is lacking on the integrated evaluation of mortality rates in healthcare-associated infections (HAIs). Our aim was to differentiate the risk factors responsible for the incidence from those for the case-fatality rates in association with HAIs. We therefore examined the time trends of both incidence and case-fatality rates over a 20-year period at a tertiary-care teaching medical centre in Taiwan and the mortality rate was expressed as the product of the incidence rate and the case-fatality rate. During the study period the overall mortality rate fell from 0·46 to 0·32 deaths/1000 patient-days and the incidence rate fell from 3·41 to 2·31/1000 patient-days, but the case-fatality rate increased marginally from 13·5% to 14·0%. The independent risk factors associated with incidence of HAIs were age, gender, infection site, admission type, and department of hospitalization. Significant prognostic factors for HAI case-fatality were age, infection site, intensive care, and clinical department. We conclude that the decreasing trend for the HAI mortality rate was accompanied by a significant decline in the incidence rate and this was offset by a slightly increasing trend in the case-fatality rate. This deconstruction approach could provide further insights into the underlying complex causes of mortality for HAIs.

Incidence of and Risk Factors for Nosocomial Bloodstream Infections in Adults in the United States, 2003

2009 ◽  
Vol 30 (11) ◽  
pp. 1036-1044 ◽  
Author(s):  
Omar M. AL-Rawajfah ◽  
Frank Stetzer ◽  
Jeanne Beauchamp Hewitt
Keyword(s):  
United States ◽  
Risk Factors ◽  
Case Fatality Rate ◽  
Nationwide Inpatient Sample ◽  
Hospital Admissions ◽  
Case Fatality ◽  
The United States ◽  
Fatality Rate ◽  
The Us ◽  
National Estimates

Background.Although many studies have examined nosocomial bloodstream infection (BSI), US national estimates of incidence and case-fatality rates have seldom been reported.Objective.The purposes of this study were to generate US national estimates of the incidence and severity of nosocomial BSI and to identify risk factors for nosocomial BSI among adults hospitalized in the United States on the basis of a national probability sample.Methods.This cross-sectional study used the US Nationwide Inpatient Sample for the year 2003 to estimate the incidence and case-fatality rate associated with nosocomial BSI in the total US population. Cases of nosocomial BSI were defined by using 1 or more International Classification of Diseases, 9th Revision, Clinical Modification codes in the secondary field(s) that corresponded to BSIs that occurred at least 48 hours after admission. The comparison group consisted of all patients without BSI codes in their NIS records. Weighted data were used to generate US national estimates of nosocomial BSIs. Logistic regression was used to identify independent risk factors for nosocomial BSI.Results.The US national estimated incidence of nosocomial BSI was 21.6 cases per 1,000 admissions, while the estimated case-fatality rate was 20.6%. Seven of the 10 leading causes of hospital admissions associated with nosocomial BSI were infection related. We estimate that 541,081 patients would have acquired a nosocomial BSI in 2003, and of these, 111,427 would have died. The final multivariate model consisted of the following risk factors: central venous catheter use (odds ratio [OR], 4.76), other infections (OR, 4.61), receipt of mechanical ventilation (OR, 4.97), trauma (OR, 1.98), hemodialysis (OR, 4.83), and malnutrition (OR, 2.50). The total maximum rescaled R2 was 0.22.Conclusions.The Nationwide Inpatient Sample was useful for estimating national incidence and case-fatality rates, as well as examining independent predictors of nosocomial BSI.

scholarly journals Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
O. V. Stanevich ◽  
D. S. Fomina ◽  
I. G. Bakulin ◽  
S. I. Galeev ◽  
E. A. Bakin ◽  
...  
Keyword(s):  
Cohort Study ◽  
Respiratory Failure ◽  
Case Fatality Rate ◽  
Case Fatality ◽  
Hospitalized Patients ◽  
High Fever ◽  
Cytokine Therapy ◽  
Fatality Rate ◽  
Matched Cohort ◽  
Matched Cohort Study

Abstract Background Several anti-cytokine therapies were tested in the randomized trials in hospitalized patients with severe acute respiratory syndrome coronavirus 2 infection (COVID-19). Previously, dexamethasone demonstrated a reduction of case-fatality rate in hospitalized patients with respiratory failure. In this matched control study we compared dexamethasone to a Janus kinase inhibitor, ruxolitinib. Methods The matched cohort study included 146 hospitalized patients with COVID-19 and oxygen support requirement. The control group was selected 1:1 from 1355 dexamethasone-treated patients and was matched by main clinical and laboratory parameters predicting survival. Recruitment period was April 7, 2020 through September 9, 2020. Results Ruxolitinib treatment in the general cohort of patients was associated with case-fatality rate similar to dexamethasone treatment: 9.6% (95% CI [4.6–14.6%]) vs 13.0% (95% CI [7.5–18.5%]) respectively (p = 0.35, OR = 0.71, 95% CI [0.31–1.57]). Median time to discharge without oxygen support requirement was also not different between these groups: 13 vs. 11 days (p = 0.13). Subgroup analysis without adjustment for multiple comparisons demonstrated a reduced case-fatality rate in ruxolitnib-treated patients with a high fever (≥ 38.5 °C) (OR 0.33, 95% CI [0.11–1.00]). Except higher incidence of grade 1 thrombocytopenia (37% vs 23%, p = 0.042), ruxolitinib therapy was associated with a better safety profile due to a reduced rate of severe cardiovascular adverse events (6.8% vs 15%, p = 0.025). For 32 patients from ruxolitinib group (21.9%) with ongoing progression of respiratory failure after 72 h of treatment, additional anti-cytokine therapy was prescribed (8–16 mg dexamethasone). Conclusions Ruxolitinib may be an alternative initial anti-cytokine therapy with comparable effectiveness in patients with potential risks of steroid administration. Patients with a high fever (≥ 38.5 °C) at admission may potentially benefit from ruxolitinib administration. Trial registration The Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness NCT04337359, CINC424A2001M, registered April, 7, 2020. First participant was recruited after registration date

scholarly journals Fetomaternal outcomes in patients with Uterine Rupture managed at Bugando Medical Centre, Tanzania: 5-year review of cases

2019 ◽  
Author(s):  
Simon Mrema ◽  
Anthony Massinde ◽  
Dismas Matovelo ◽  
Albert Kihunrwa ◽  
Richard Rumanyika ◽  
...  
Keyword(s):  
Risk Factors ◽  
Uterine Rupture ◽  
Case Fatality Rate ◽  
Case Fatality ◽  
Maternal Outcomes ◽  
Fatality Rate ◽  
Obstructed Labor ◽  
Apgar Scores ◽  
Bugando Medical ◽  
Bugando Medical Centre

Abstract Background Uterine rupture is one of the major obstetric complications, associated with adverse fetal and maternal outcomes including hemorrhage, genital urinary injury, low Apgar scores, fetomaternal deaths. There is a paucity of data regarding uterine rupture and its consequences among pregnant women in Mwanza, Tanzania. As a result, it is difficult to know the magnitude of the problem and formulate appropriate measures to reduce its incidence. This study was thus conducted to determine the cumulative incidence, risk factors, fetal and maternal outcomes among women with uterine rupture managed at Bugando Medical Centre (BMC), Mwanza-Tanzania.Methods This was a 5-year (2013 to 2017) retrospective descriptive study of cases of uterine rupture at BMC. The case files were collected from medical records department and maternal demographic information, clinical presentation, risk factors, interventions and feto-maternal outcomes were extracted using a checklist. Data were analyzed using STATA software version 13.Results There were 37,763 deliveries within five years. Caesarean section accounted for a quarter (n=9,136) of these deliveries. During this period 81 cases of ruptured uterus were identified, making a cumulative incidence of 2.2 cases per 1,000 deliveries. Common risk factors for uterine rupture were history of previous caesarean section 54% (n=36), obstructed labor 37% (n=25), grandmultiparity 19.4% (n=13) and use of oxytocin 21% (n=14). Maternal case fatality rate in this study was 1.5% (n=1). More than half of cases had hysterectomy while about a third (n=25) had uterine repair without bilateral tubal ligation (BTL). Over 80% (n=55) of cases required blood transfusion. Sepsis developed in 21% (n=14) of cases and vesicovaginal fistula (VVF) in 12% (n=8). Perinatal case fatality rate was 72% (n=48). Out of the 24 babies who were born alive, 37.5% (n=9) had low Apgar scores and 20.8% (n=5) died before discharge.Conclusion The leading risk factor for uterine rupture seen was previous caesarean scar and obstructed labor associated with high perinatal case fatality rate. Improvement in monitoring of patients in labor is necessary to detect early features of uterine rupture, obstructed labour and fetal compromise. This will contribute to reduced incidence of uterine rupture and improve fetomaternal outcomes.

scholarly journals Case fatality rate in COVID-19: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Chanaka Kahathuduwa ◽  
Chathurika Dhanasekara ◽  
Shao-Hua Chin
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Critical Illness ◽  
Publication Bias ◽  
Case Fatality Rate ◽  
Meta Analysis ◽  
Case Fatality ◽  
Severe Illness ◽  
Fatality Rate ◽  
Meta Regression

AbstractBackgroundEstimating the prevalence of severe or critical illness and case fatality of COVID-19 outbreak in December, 2019 remains a challenge due to biases associated with surveillance, data synthesis and reporting. We aimed to address this limitation in a systematic review and meta-analysis and to examine the clinical, biochemical and radiological risk factors in a meta-regression.MethodsPRISMA guidelines were followed. PubMed, Scopus and Web of Science were searched using pre-specified keywords on March 07, 2020. Peer-reviewed empirical studies examining rates of severe illness, critical illness and case fatality among COVID-19 patients were examined. Numerators and denominators to compute the prevalence rates and risk factors were extracted. Random-effects meta-analyses were performed. Results were corrected for publication bias. Meta-regression analyses examined the moderator effects of potential risk factors.ResultsThe meta-analysis included 29 studies representing 2,090 individuals. Pooled rates of severe illness, critical illness and case fatality among COVID-19 patients were 15%, 5% and 0.8% respectively. Adjusting for potential underreporting and publication bias, increased these estimates to 26%, 16% and 7.4% respectively. Increasing age and elevated LDH consistently predicted severe / critical disease and case fatality. Hypertension; fever and dyspnea at presentation; and elevated CRP predicted increased severity.ConclusionsRisk factors that emerged in our analyses predicting severity and case fatality should inform clinicians to define endophenotypes possessing a greater risk. Estimated case fatality rate of 7.4% after correcting for publication bias underscores the importance of strict adherence to preventive measures, case detection, surveillance and reporting.

scholarly journals Incidence and case fatality rate of COVID-19 in patients with active epilepsy

Neurology ◽  
2020 ◽  
Vol 95 (10) ◽  
pp. e1417-e1425 ◽  
Author(s):  
Pablo Cabezudo-García ◽  
Nicolás Lundahl Ciano-Petersen ◽  
Natalia Mena-Vázquez ◽  
Gracia Pons-Pons ◽  
María Victoria Castro-Sánchez ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cumulative Incidence ◽  
Case Fatality Rate ◽  
Multiple Logistic Regression Analysis ◽  
Case Fatality ◽  
Control Group ◽  
Fatality Rate ◽  
Number Of Patients ◽  
Active Epilepsy ◽  
Patients With Epilepsy

ObjectiveThis article estimates the incidence and fatality of coronavirus disease 2019 (COVID-19) and identifies potential risk factors for fatality in patients with active epilepsy.MethodsThis is a cross-sectional observational study of patients with active epilepsy and COVID-19. A control group was used to compare the cumulative incidence and case-fatality rate (CFR). The main outcomes of the study were cumulative incidence, defined as number of patients with active epilepsy and COVID-19 admitted to an emergency department divided by the total number of patients with epilepsy at risk, and CFR based on the number of deaths during the enrollment period. Multiple logistic regression analysis was performed to investigate risk factors for fatality in patients with active epilepsy.ResultsOf the 1,537 patients who fulfilled the inclusion criteria, 21 (1.3%) had active epilepsy. The cumulative incidence (95% confidence interval [CI]) of COVID-19 in patients with epilepsy was higher (1.2% [0.6–2.4]) compared to the population without epilepsy (0.5% [0.5–0.5]). In reverse transcription PCR–positive patients, there were no significant differences in CFR in patients with active epilepsy compared to patients without epilepsy (33.3% vs 8.3%; p = 0.266). Of the 21 patients with active epilepsy, 5 (23%) died. In multivariate analysis, the factor associated with fatality in patients with active epilepsy was hypertension (odds ratio [OR] 2.8 [95% CI 1.3–21.6]). In another model, age (OR 1.0 [95% CI 1.0–1.1]) and epilepsy (OR 5.1 [95% CI 1.3–24.0]) were associated with fatality during hospitalization.ConclusionCOVID-19 cumulative incidence was higher in patients with active epilepsy. Epilepsy was associated with fatality during hospitalization. Hypertension was associated with fatality in patients with epilepsy.

Sign in / Sign up

Export Citation Format

Share Document